Mechanical stress can strongly influence the capability of a protein to aggregate and the kinetics of aggregation, but there is little insight into the underlying mechanism. Here we study the effect ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings reveal significant differences in splanchnic and leg glucagon metabolism.

Ananda Basu, M.D. A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 ...

Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.. If you have the appropriate software installed, ...

Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.. If you have the appropriate software installed, you can ...

Holst, Habener, and Drucker — who joined Habener’s lab in the mid-1980s — went on to characterize the biology and mechanism of GLP-1. They showed that food intake prompts the gut to release the ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

Opko and Entera have formalized their partnership as the biotechs prepare to take the first oral dual agonist GLP-1/glucagon peptide into the clinic.

The increase in glucagon then signals the liver to release glucose. “When we blocked these cytokines, glucagon levels dropped, proving they are essential for maintaining blood sugar levels”.

Glucagon prescriptions for severe hypoglycemia rose in Medicaid beneficiaries with the introduction of newer products but likely met only a fraction of the high-risk population’s needs.

As a counter to insulin, glucagon plays a vital role in diabetes, maintaining blood sugar levels and offering therapeutic potential for hypoglycemia.